2228 (2228) Fair Value & Analysis
Healthcare · Market cap HK$32.9B
Fair value as of: Jul 2, 2026
From 12 valuation models · updated today
Share price −6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$5.35 – HK$14.87 · fair‑value band HK$0.7200 – HK$1.16 · the HK$7.48 price screens above the HK$1.03 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2228 (2228) currently trades at HK$7.48, while our model-based Fair Value estimate is HK$1.03 — implying the stock looks roughly 86.2% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, 2228 generated revenue of HK$803M at a net margin of 15.4%. Revenue grew 74.3% year over year. It earns a return on equity of 2.0%. The balance sheet holds a net cash position of HK$2.1B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2228 reported revenue of HK$782M in FY2025 versus HK$62.8M in FY2021, a compound +87.8%/yr. Reported net income was HK$121M in FY2025.
Is 2228 fairly valued? → Check now
Recent news
- XtalPi Holdings (SEHK:2228) Stock Valuation Check After Recent Weak Momentum
- XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
- XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
- XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $86.03 | $54.47 | -37% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2228 (2228) undervalued?
What is the fair value of 2228?
What is the quality score of 2228?
What is the revenue of 2228 (2228)?
What is the net profit margin of 2228?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.